Moderna and Merck Melanoma Vaccine Succeeds in Phase 3 Trial

Phase 3 Trial Success and Study Details

The late-stage study enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma. Earlier mid-stage five-year data presented in June showed that adding the vaccine to Keytruda cut the risk of cancer returning or death by 49%, and reduced the risk of distant metastasis or death by 59%, compared with Keytruda alone.

How the Personalized Vaccine Works

Unlike preventive vaccines designed to ward off infections, intismeran autogene is a therapeutic treatment administered to patients who already have cancer. The therapy is tailored specifically to each individual. After surgical removal of the melanoma, a sample of the patient’s tumor is analyzed to identify mutations unique to those cancer cells. Messenger RNA technology is then used to provide genetic instructions corresponding to selected tumor-specific neoantigens, which act as molecular flags distinguishing cancer cells from healthy tissue.

This customized jab trains the patient’s immune system—particularly T cells—to recognize and attack those specific targets. The approach combines two complementary strategies: the vaccine teaches the immune system what targets to look for, while pembrolizumab removes natural brakes that can prevent immune cells from attacking cancer. According to channelnewsasia.com, each custom-made vaccine for the trial took six to eight weeks to develop.

History of the Partnership and Development

The breakthrough marks the first successful late-stage testing of a therapeutic cancer vaccine after more than a century of prior failed attempts. Stéphane Bancel, CEO of Moderna, received news of the successful trial late on August 13 while celebrating a friend’s birthday at a Lebanese restaurant. Bancel compared the milestone to the moment Moderna announced its COVID-19 vaccine trial results in late 2020.

Moderna and Merck Achieve Breakthrough with Personalized Melanoma Treatment

The collaboration between Moderna and Merck spans a decade. The companies announced a partnership in 2016 after working for over a year on a separate vaccine venture. For the cancer collaboration, Merck paid $200 million upfront in 2016 and an additional $250 million in 2022, with both companies sharing costs and profits. Tal Zaks, who served as Moderna’s chief medical officer from 2015 to 2021, noted that earlier generations failed for many years, but modern advancements combining mRNA technology, checkpoint inhibitors like Keytruda, and cheaper genetic sequencing finally opened a path toward success.

Future Pipeline and Regulatory Next Steps

Following the positive Phase 3 readout, the companies are preparing to begin regulatory filings while planning to present full trial data at an upcoming medical meeting. Beyond melanoma, Moderna and Merck are already running additional clinical trials evaluating the same vaccine and Keytruda combination across several other tumor types, including lung, bladder, kidney, pancreatic, and stomach cancers.

While experts have emphasized caution because full trial results remain pending and further follow-up is ongoing to determine overall survival effects, industry observers view the platform technology as holding broad potential. Analysts note that commercial availability will depend on successful regulatory review, and logistical considerations may shape how quickly the personalized therapy reaches patients outside major research hospitals.

Summary of Trial and Vaccine Characteristics

Metric / Feature	Details
Trial Name & Size	INTerpath-001; 1,137 patients with completely resected stage IIB-IV cutaneous melanoma
Primary Endpoint	Recurrence-free survival
Secondary Endpoint	Distant metastasis-free survival
Treatment Regimen	Intismeran autogene (V940 / mRNA-4157) plus pembrolizumab vs. pembrolizumab alone
Production Timeline	Custom-made within six to eight weeks based on individual tumor genetics